Source:http://linkedlifedata.com/resource/pubmed/id/10521803
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1999-11-19
|
pubmed:abstractText |
Bombesin (BN) is a 14-amino-acid neuropeptide with a high affinity for the gastrin-releasing peptide receptor. This receptor has been found to be expressed in a variety of tumours, including lung, breast, prostate and pancreas. A newly synthesized BN analogue, [DTPA-Pro(1),Tyr(4)]BN, was shown to be a high-affinity BN-receptor (BNR) agonist, stimulating prolactin secretion from 7315b cells with an IC(50) of 8 nM. The (111)In-labelled analogue was found to bind with high affinity to rat BNR in vitro and in vivo. The radioligand is internalized by BNR-expressing cells, in contrast to DTPA-conjugated BN antagonists. Therefore, we further studied the biodistribution of i.v. injected [(111)In-DTPA-Pro(1),Tyr(4)]BN in rats. High and specific uptake was found in tissues of the gastrointestinal tract, notably pancreas. Uptake of radioactivity was blocked by pre- or co-injection of 100 microgram [Tyr(4)]BN, but not when this was administered 30 min after the radioligand. This suggests BNR-mediated internalization of the radioligand within 30 min. The percentage injected dose (ID) taken up by BNR-positive tissues was a bell-shaped function of the amount (0.01-0.1 microgram) of injected ligand. Next to the pancreas, highest uptake was observed in the kidneys, which was not blocked by excess [Tyr(4)]BN. Dynamic gamma camera studies showed rapid clearance of radioactivity from the blood compartment. Urinary excretion amounted to about 35% ID after 1 hr and to 70% ID after 24 hr, with a total body retention of 10% ID. Specific uptake was found in the BNR-positive CA20948 pancreas tumour and CC531 colon carcinoma in tumour-bearing rats. The CA20948 tumour, inoculated in the hindleg, was also visualized scintigraphically. [(111)In-DTPA-Pro(1), Tyr(4)]BN appears to be a promising radioligand for scintigraphy of BNR-expressing tumours.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bombesin,
http://linkedlifedata.com/resource/pubmed/chemical/Indium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Pentetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Bombesin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 1999 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
26
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
657-63
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:10521803-Animals,
pubmed-meshheading:10521803-Bombesin,
pubmed-meshheading:10521803-Drug Evaluation, Preclinical,
pubmed-meshheading:10521803-Indium Radioisotopes,
pubmed-meshheading:10521803-Male,
pubmed-meshheading:10521803-Pentetic Acid,
pubmed-meshheading:10521803-Radiopharmaceuticals,
pubmed-meshheading:10521803-Rats,
pubmed-meshheading:10521803-Rats, Inbred Lew,
pubmed-meshheading:10521803-Receptors, Bombesin,
pubmed-meshheading:10521803-Tissue Distribution
|
pubmed:year |
1999
|
pubmed:articleTitle |
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy.
|
pubmed:affiliation |
Department of Nuclear Medicine, University Hospital "Dijkzigt," Rotterdam, The Netherlands. breeman@nuge.azr.nl
|
pubmed:publicationType |
Journal Article
|